CN110496144A - Preparation method of kiwi fruit extract and its application in preventing and treating cardiovascular and cerebrovascular diseases - Google Patents
Preparation method of kiwi fruit extract and its application in preventing and treating cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN110496144A CN110496144A CN201910748101.XA CN201910748101A CN110496144A CN 110496144 A CN110496144 A CN 110496144A CN 201910748101 A CN201910748101 A CN 201910748101A CN 110496144 A CN110496144 A CN 110496144A
- Authority
- CN
- China
- Prior art keywords
- extract
- kiwi fruit
- preparation
- fruit extract
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 23
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 22
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 21
- 229940055350 kiwi fruit extract Drugs 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 244000298697 Actinidia deliciosa Species 0.000 claims abstract description 25
- 235000009436 Actinidia deliciosa Nutrition 0.000 claims abstract description 22
- 239000000284 extract Substances 0.000 claims abstract description 14
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 238000004042 decolorization Methods 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 7
- 239000012535 impurity Substances 0.000 claims abstract description 7
- 238000001556 precipitation Methods 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000004927 clay Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims 2
- 238000007598 dipping method Methods 0.000 claims 1
- 238000007654 immersion Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 210000004369 blood Anatomy 0.000 abstract description 18
- 239000008280 blood Substances 0.000 abstract description 18
- 235000013399 edible fruits Nutrition 0.000 abstract description 13
- 150000002632 lipids Chemical class 0.000 abstract description 9
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 4
- 210000004185 liver Anatomy 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 230000002019 anti-mutation Effects 0.000 abstract description 3
- 230000002155 anti-virotic effect Effects 0.000 abstract description 3
- 230000036772 blood pressure Effects 0.000 abstract description 3
- 230000000857 drug effect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 241000286209 Phasianidae Species 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000000518 rheometry Methods 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 244000298715 Actinidia chinensis Species 0.000 description 2
- 235000009434 Actinidia chinensis Nutrition 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 238000005470 impregnation Methods 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 208000004124 rheumatic heart disease Diseases 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 241000590988 Danainae Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及植物及其应用技术领域,猕猴桃提取物制备方法包括制备提取液、沉淀、除杂、脱色、干燥、粉碎,得到猕猴桃提取物干品;本发明采用猕猴桃果实、叶、枝和根提取物作为在防治心脑血管疾病的应用,因为果实有降血压、血脂、抗氧化、抗炎、改善血液流变学等防治AS药效;根具有抗肿瘤、抗炎、抗病毒、抗突变、抗氧化和保肝、提高免疫力、降血脂等多种活性;根、茎、果实等药用部位都具有抗肿瘤作用和保肝作用。
The invention relates to the technical field of plants and their applications. The preparation method of kiwifruit extract includes preparing extract, precipitation, impurity removal, decolorization, drying and crushing to obtain dry kiwifruit extract; the invention adopts kiwifruit fruit, leaves, branches and roots to extract As an application in the prevention and treatment of cardiovascular and cerebrovascular diseases, because the fruit has anti-AS drug effects such as lowering blood pressure, blood lipids, anti-oxidation, anti-inflammation, and improving hemorheology; the root has anti-tumor, anti-inflammation, anti-virus, anti-mutation, It has various activities such as anti-oxidation and liver protection, improving immunity, and lowering blood lipids; medicinal parts such as roots, stems, and fruits have anti-tumor and liver-protecting effects.
Description
技术领域technical field
本发明涉及植物及其应用技术领域,具体涉及一种猕猴桃提取物制备方法及其防治心脑血管疾病的应用。The invention relates to the technical field of plants and their applications, in particular to a preparation method of a kiwi fruit extract and its application in preventing and treating cardiovascular and cerebrovascular diseases.
背景技术Background technique
心脑血管疾病(CVD)是心血管疾病和脑血管疾病的统称,其主要病理基础是动脉粥样硬化(atherosclerosis,AS);现代人群中常见的心脑血管疾病包括脑血管疾病、冠心病、心肌梗死、中风、风湿性心脏病及肺源性心脏病等。心脑血管疾病是严重威胁当今人类生命健康的疾病,已成为世界大多数国家第一二位死亡原因;据世界卫生组织最新统计结果,在过去十年中全球十大死因前两位的分别是冠心病和中风;中国居民病因死亡构成中心脑血管病在城市居民占41.1%、在农村居民占38.7%,是我国居民的头号杀手。Cardiovascular and cerebrovascular disease (CVD) is a general term for cardiovascular and cerebrovascular diseases, and its main pathological basis is atherosclerosis (AS); common cardiovascular and cerebrovascular diseases in the modern population include cerebrovascular disease, coronary heart disease, Myocardial infarction, stroke, rheumatic heart disease and cor pulmonale, etc. Cardiovascular and cerebrovascular diseases are diseases that seriously threaten human life and health today, and have become the first and second causes of death in most countries in the world; according to the latest statistics from the World Health Organization, the top two causes of death in the world in the past ten years are Coronary heart disease and apoplexy: Cardiovascular disease accounts for 41.1% of urban residents and 38.7% of rural residents, and is the number one killer of Chinese residents.
西医认为导致心脑血管疾病的危险因素为高血脂、吸烟、高血压、糖尿病、肥胖、代谢综合征、氧化应激、感染和炎症反应等。除了一些急性感染性病症如心肌炎和风湿性心脏病外,大部分心脑血管疾病在急性发病之后漫长的缓解期间需要持续不断的药物治疗以防止心脑血管疾病复发。化学药和生物药效果直接、迅速,但作用功效单一、毒副作用大,不适合长期的调理和治疗;而中药具有“多靶点、多效应、毒副作用小”等优点,防治心脑血管疾病更有优势,适合长期服用。Western medicine believes that the risk factors for cardiovascular and cerebrovascular diseases are hyperlipidemia, smoking, hypertension, diabetes, obesity, metabolic syndrome, oxidative stress, infection, and inflammatory response. Except for some acute infectious diseases such as myocarditis and rheumatic heart disease, most cardiovascular and cerebrovascular diseases require continuous drug treatment during the long remission period after the acute onset to prevent the recurrence of cardiovascular and cerebrovascular diseases. Chemical drugs and biological drugs have direct and rapid effects, but they have single effects and large toxic and side effects, which are not suitable for long-term conditioning and treatment; while traditional Chinese medicine has the advantages of "multi-target, multi-effect, and small toxic and side effects" to prevent and treat cardiovascular and cerebrovascular diseases More advantages, suitable for long-term use.
猕猴桃(Actinidia chinensis)果实味甘、酸,性寒,入脾、胃经,实热者宜食之,具有调中理气、止暴渴、解烦热、下石淋热壅等功效;全株味淡、涩、性平,清热毒。猕猴桃在中国很多地方都有种植,其中红心猕猴桃作为一项扶贫产业在广西、贵州等一些国家级贫困地区完成了大面积的种植。然而猕猴桃不易保鲜、皮薄,长途运输易损坏导致这两年大量猕猴桃产品积压、滞销,给种植户造成极大损失,沉重打击了居民种植积极性。目前虽有使用猕猴桃果实去皮晒干后压制成果脯,猕猴桃果实发酵或与其它药材配方饮料或保健品的专利,但缺乏其产品的药用、营养保健价值的研究而导致其难于推广、生产,无法解决猕猴桃积压和滞销问题。Actinidia chinensis (Actinidia chinensis) fruit is sweet, sour, and cold in nature. It enters the spleen and stomach meridians. People with excessive heat should eat it. Mild in taste, astringent, flat in nature, clearing away heat and poison. Kiwifruit is grown in many places in China, and red kiwifruit has been planted on a large scale in Guangxi, Guizhou and other national-level poverty-stricken areas as a poverty alleviation industry. However, kiwifruit is not easy to keep fresh, its skin is thin, and it is easily damaged during long-distance transportation. In the past two years, a large number of kiwifruit products have been backlogged and unsalable, causing great losses to growers and a heavy blow to residents' enthusiasm for planting. At present, although there are patents for using kiwi fruit peeled and dried to suppress fruit preserves, fermented kiwi fruit or formulating beverages or health products with other medicinal materials, the lack of research on the medicinal and nutritional health value of its products makes it difficult to promote and produce. , unable to solve the problem of kiwi fruit backlog and slow sales.
因此,针对心脑血管疾病的防治应当充分挖掘民族医药,针对猕猴桃种植业面临的困境应当充分挖掘猕猴桃各部位药用价值,研发具有副作用少、成本低、易吸收、加工简、易推广的猕猴桃各部位配方,从而在心脑血管疾病预防、治疗以及猕猴桃经济价值上都取得更好效果。Therefore, for the prevention and treatment of cardiovascular and cerebrovascular diseases, ethnic medicine should be fully tapped, and the medicinal value of various parts of kiwifruit should be fully tapped for the difficulties faced by the kiwifruit planting industry, and kiwifruit with fewer side effects, low cost, easy absorption, simple processing, and easy promotion should be developed. The formulation of each part can achieve better results in the prevention and treatment of cardiovascular and cerebrovascular diseases and the economic value of kiwi fruit.
发明内容Contents of the invention
本发明的目的在于提供一种改善心脑血管疾病的猕猴桃提取物及其制备方法和用途,以解决上述背景技术中所提出的问题。The object of the present invention is to provide a kiwi fruit extract for improving cardiovascular and cerebrovascular diseases and its preparation method and application, so as to solve the problems raised in the above-mentioned background technology.
为实现上述目的,本发明提供如下技术方案:To achieve the above object, the present invention provides the following technical solutions:
一种猕猴桃提取物制备方法,包括以下步骤:A kind of kiwi fruit extract preparation method, comprises the following steps:
(A)、制备提取液(A), preparation of extract
将猕猴桃果实、叶、枝和根洗净混合平磨成粉,取粗粉1Kg,依次使用90%、50%和10%的乙醇20-60℃浸渍3次,每次18-30小时,取上清液,合并;Wash the kiwifruit fruit, leaves, branches and roots, mix and grind them into powder, take 1Kg of coarse powder, use 90%, 50% and 10% ethanol in turn to soak 3 times at 20-60°C, each time for 18-30 hours, take supernatant, combined;
猕猴桃各部位的药效:The medicinal effect of each part of kiwi fruit:
果实味甘、酸、寒,无毒,入脾、胃经,实热者宜食之,具有调中理气、止暴渴、解烦热、下石淋热壅等功效;根具有清热、利尿、活血、消肿的功效;汁甘、滑、寒,无毒,下石淋,与生姜汁服治热壅反胃;枝叶杀虫、疗瘑疥;全株味淡、涩、性平,清热毒。The fruit tastes sweet, sour, cold, and non-toxic. It enters the spleen and stomach meridians. It is suitable for people with excessive heat. , promoting blood circulation, and reducing swelling; the juice is sweet, slippery, cold, non-toxic, poured into the stone, and taken with ginger juice to treat heat and nausea; branches and leaves kill insects and treat scabies; the whole plant is light in taste, astringent, flat in nature, clearing away heat poison.
现代药理学研究结果表明,果实有降血压、血脂、抗氧化、抗炎、改善血液流变学等防治AS药效;根具有抗肿瘤、抗炎、抗病毒、抗突变、抗氧化和保肝、提高免疫力、降血脂等多种活性;根、茎、果实等药用部位都具有抗肿瘤作用和保肝作用。Modern pharmacological research results show that the fruit has the effects of lowering blood pressure, blood lipids, anti-oxidation, anti-inflammation, and improving hemorheology; the root has anti-tumor, anti-inflammatory, anti-virus, anti-mutation, anti-oxidation, and liver protection. , Improving immunity, lowering blood lipids and other activities; medicinal parts such as roots, stems, and fruits have anti-tumor effects and liver-protecting effects.
(B)、沉淀(B), precipitation
在步骤(A)的提取液中加乙醇调至含乙醇量为90-95%,静置,离心处理,得到澄清液;沉淀物再用50-80%的乙醇和水各洗涤2次并离心处理,取澄清液弃沉淀;Add ethanol to the extract in step (A) to adjust the ethanol content to 90-95%, let stand, and centrifuge to obtain a clarified liquid; the precipitate is then washed twice with 50-80% ethanol and water and centrifuged For processing, take the clarified solution and discard the precipitate;
(C)、除杂、脱色(C), impurity removal, decolorization
在(B)澄清液中加入活性炭:活性白土=1:10的混合脱色剂2000g除杂脱色,脱色后溶液呈极淡黄绿色;Add activated carbon to (B) clarified liquid: activated clay = 1:10 mixed decolorizing agent 2000g to remove impurities and decolorize, the solution after decolorization is very light yellow-green;
(D)、干燥、粉碎(D), drying, crushing
将脱色后的澄清液于减压浓缩装置中与50-55℃中减压浓缩,浓缩液放入减压干燥箱中,于40-58℃条件下减压干燥约48小时,真空度为-0.08至-0.1MPa,得到猕猴桃提取物干品。Concentrate the decolorized clear liquid in a vacuum concentrator at 50-55°C under reduced pressure, put the concentrated liquid in a reduced-pressure drying oven, and dry it under reduced pressure at 40-58°C for about 48 hours. The vacuum degree is - 0.08 to -0.1MPa to obtain the dry product of kiwi fruit extract.
进一步的,所述步骤(A)中各比例乙醇的用量为5升,在浸渍过程每隔两个小时搅拌一次,搅拌时间为15分钟,浸渍完成后过滤,收集上清液。Further, the amount of ethanol in each proportion in the step (A) is 5 liters, and the impregnation process is stirred once every two hours for 15 minutes. After the impregnation is completed, filter and collect the supernatant.
进一步的,步骤(D)中真空度为-0.06至-0.05MPa,保持温度在50-55℃,浓缩12-15倍。Further, in step (D), the degree of vacuum is -0.06 to -0.05MPa, the temperature is kept at 50-55°C, and the concentration is 12-15 times.
步骤(D)中真空度为-0.55MPa,保持温度在55℃,浓缩13倍。In step (D), the vacuum degree is -0.55MPa, the temperature is kept at 55°C, and the concentration is 13 times.
在本发明中,一种猕猴桃提取物采用上述方法制备得到。本发明所述的猕猴桃提取物在防治心脑血管疾病的应用。In the present invention, a kiwi fruit extract is prepared by the above method. The application of the kiwifruit extract of the invention in the prevention and treatment of cardiovascular and cerebrovascular diseases.
与现有技术相比,本发明的有益效果是:Compared with prior art, the beneficial effect of the present invention is:
本发明采用猕猴桃果实、叶、枝和根提取物作为在防治心脑血管疾病的应用,因为果实有降血压、血脂、抗氧化、抗炎、改善血液流变学等防治AS药效;根具有抗肿瘤、抗炎、抗病毒、抗突变、抗氧化和保肝、提高免疫力、降血脂等多种活性;根、茎、果实等药用部位都具有抗肿瘤作用和保肝作用;猕猴桃各部位合用体现中药君臣佐史配伍思想,同类药效相加和、异类药效相互补充这样一种多成分、多靶点、协同作用增强降血脂、改善血液流变学、抗炎、抗氧化等防治心脑血管疾病药效。The present invention adopts kiwifruit fruit, leaves, branches and root extracts as the application of prevention and treatment of cardiovascular and cerebrovascular diseases, because the fruit has anti-AS drug effects such as lowering blood pressure, blood fat, anti-oxidation, anti-inflammation, and improving blood rheology; the root has Anti-tumor, anti-inflammation, anti-virus, anti-mutation, anti-oxidation and liver protection, improving immunity, lowering blood lipids and other activities; medicinal parts such as roots, stems, and fruits have anti-tumor and liver protection effects; The combination of parts embodies the idea of compatibility of traditional Chinese medicine monarchs, ministers, and history. The effects of similar drugs are added together, and the effects of different drugs complement each other. This kind of multi-component, multi-target, and synergistic effect can enhance blood lipid reduction, improve blood rheology, anti-inflammatory, anti-oxidation, etc. Prevention and treatment of cardiovascular and cerebrovascular diseases.
猕猴桃各部位是中医学中常用易得的药物,且成本低廉、加工简单。根据患者病情及需要可加工成丸剂、汤剂,易于服用;同时,针对心脑血管疾病病因通过降血脂、改善血液流变学、抗炎、抗氧化、增强免疫力等多方面预防与治疗;所用药材属于天然药物且各部位均无毒,配伍后药性平和,体热、体寒者均可长期服用,避免长期服用化学合成药物带来的副作用和耐药性,符合心脑血管疾病防治用药特点。The various parts of kiwi fruit are commonly used and easy-to-obtain medicines in traditional Chinese medicine, and they are low in cost and easy to process. According to the patient's condition and needs, it can be processed into pills and decoctions, which are easy to take; at the same time, it can be used to prevent and treat cardiovascular and cerebrovascular diseases by reducing blood lipids, improving blood rheology, anti-inflammation, anti-oxidation, and enhancing immunity; The medicinal materials used are natural medicines and all parts are non-toxic. After compatibility, the medicinal properties are mild, and those with body heat and cold can take it for a long time, avoiding the side effects and drug resistance caused by long-term use of chemically synthesized drugs, and complying with the prevention and treatment of cardiovascular and cerebrovascular diseases. features.
附图说明Description of drawings
图1是本发明提取物用于防治心脑血管疾病实验结果。Fig. 1 is the experimental result of the extract of the present invention being used to prevent and treat cardiovascular and cerebrovascular diseases.
具体实施方式Detailed ways
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。The following will clearly and completely describe the technical solutions in the embodiments of the present invention with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only some of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without making creative efforts belong to the protection scope of the present invention.
实施例1:制备对猕猴桃全株提取物:Embodiment 1: prepare the whole plant extract of kiwifruit:
(A)、制备提取液(A), preparation of extract
将猕猴桃果实、叶、枝和根洗净混合平磨成粉,取粗粉1Kg,依次使用90%、50%和10%的乙醇20-60℃浸渍3次,每次18-30小时,取上清液,合并;Wash the kiwifruit fruit, leaves, branches and roots, mix and grind them into powder, take 1Kg of coarse powder, use 90%, 50% and 10% ethanol in turn to soak 3 times at 20-60°C, each time for 18-30 hours, take supernatant, combined;
(B)、沉淀(B), precipitation
在步骤(A)的提取液中加乙醇调至含乙醇量为90-95%,静置,离心处理,得到澄清液;沉淀物再用50-80%的乙醇和水各洗涤2次并离心处理,取澄清液弃沉淀;Add ethanol to the extract in step (A) to adjust the ethanol content to 90-95%, let stand, and centrifuge to obtain a clarified liquid; the precipitate is then washed twice with 50-80% ethanol and water and centrifuged For processing, take the clarified solution and discard the precipitate;
(C)、除杂、脱色(C), impurity removal, decolorization
在(B)澄清液中加入活性炭:活性白土=1:10的混合脱色剂2000g除杂脱色,脱色后溶液呈极淡黄绿色;Add activated carbon to (B) clarified liquid: activated clay = 1:10 mixed decolorizing agent 2000g to remove impurities and decolorize, the solution after decolorization is very light yellow-green;
(D)、干燥、粉碎(D), drying, crushing
将脱色后的澄清液于减压浓缩装置中与50-55℃中减压浓缩,浓缩液放入减压干燥箱中,于40-58℃条件下减压干燥约48小时,真空度为-0.08至-0.1MPa,得到猕猴桃提取物干品。Concentrate the decolorized clear liquid in a vacuum concentrator at 50-55°C under reduced pressure, put the concentrated liquid in a reduced-pressure drying oven, and dry it under reduced pressure at 40-58°C for about 48 hours. The vacuum degree is - 0.08 to -0.1MPa to obtain the dry product of kiwi fruit extract.
实施例2:在58℃条件下减压干燥约48小时,真空度为-0.55MPa,保持温度在55℃,浓缩13倍,其余与实施例1相同。Example 2: Dry under reduced pressure at 58°C for about 48 hours, the vacuum degree is -0.55MPa, keep the temperature at 55°C, concentrate 13 times, and the rest are the same as in Example 1.
实施例3:对猕猴桃全株提取物的药效学实验:Embodiment 3: to the pharmacodynamic experiment of kiwi fruit whole plant extract:
①试验动物:清洁型新西兰家兔24只,雌雄各半,体重(2.25±0.25)kg,分空白组、实验组和模型组,每组8只,单笼饲养。清洁型黄羽系鹌鹑30只,5周龄,雌雄各半,体重(90±20)g,分空白组、实验组和模型组,每组10只,每组一笼饲养。① Experimental animals: 24 clean New Zealand rabbits, half male and half male, weighing (2.25±0.25) kg, divided into blank group, experimental group and model group, with 8 rabbits in each group, reared in a single cage. 30 clean-type yellow-feathered quails, 5 weeks old, half male and half male, weighing (90±20) g, were divided into blank group, experimental group and model group, 10 in each group, and raised in one cage for each group.
②髙脂饲料制备:鹌鹑髙脂饲料配方为胆固醇1%、花生油6%、猪油14%、基础饲料79%。家兔髙脂饲料配方为1.0%胆固醇、8%猪油、4%蛋黄粉、87.0%基础饲料。②Preparation of high-fat feed: the formula of high-fat feed for quail was 1% cholesterol, 6% peanut oil, 14% lard, and 79% basic feed. The formula of high-fat feed for rabbits was 1.0% cholesterol, 8% lard, 4% egg yolk powder, and 87.0% basal feed.
③试验方法:猕猴桃各部位按照一定比例混合后依次使用90%乙醇、50%乙醇和沸水提取,各梯度提取液混合并减压浓缩,空白组喂食正常饲料;实验组喂食髙脂饲料并口服本发明提取物;模型组喂食髙脂饲料;鹌鹑喂食量不固定,家兔每天每只喂食120g;鹌鹑模型每天按2.50ml/kg(相当于3g全株提取物/kg)本发明提取物1次,连续饲养42天;家兔模型每天按7.3g提取物/只给药,连续饲养60天。实验分别于实验0和60d耳缘静脉取血分析血脂五项、血液流变学、SOD等血液指标,实验结束耳缘静脉取血后乌拉坦麻醉下解剖动物,迅速取出心脏及主动脉;将主动脉从心脏与主动脉连接的位置及髂动脉分支处剪断,离体后纵向剪开主动脉并剥离动脉外膜,标本予10%中性福尔马林溶液固定,待苏丹IV染色及病理检查。。③Test method: each part of kiwi fruit was mixed according to a certain proportion and then extracted with 90% ethanol, 50% ethanol and boiling water in sequence. The gradient extracts were mixed and concentrated under reduced pressure. The blank group was fed normal feed; the experimental group was fed high-fat feed and oral administration of this product Invent the extract; the model group is fed high-fat feed; the amount of quail feeding is not fixed, and each rabbit is fed 120g every day; the quail model is 2.50ml/kg (equivalent to 3g whole plant extract/kg) the extract of the present invention once a day , fed continuously for 42 days; the rabbit model was fed 7.3g extract/only every day, and fed continuously for 60 days. In the experiment, blood was taken from the ear vein on the 0th and 60th day of the experiment to analyze blood lipids, blood rheology, SOD and other blood indicators. After the end of the experiment, after the blood was taken from the ear vein, the animal was dissected under urethane anesthesia, and the heart and aorta were quickly taken out; The aorta was cut from the position where the heart connects to the aorta and the branch of the iliac artery. After isolation, the aorta was cut longitudinally and the adventitia was stripped off. The specimen was fixed in 10% neutral formalin solution, and the Sudan IV staining and pathology were performed. examine. .
实验结果参见表1、表2、表3、表4及图1,经统计学分析,结果显示采用本发明提取物对鹌鹑、家兔甘油三酯、总胆固醇、低密度脂蛋白均高于正常组但明显低于模型组且其差异均具有统计意义,表明本药物具有较好的降血脂作用;血液流变学指标显示本药能有效降低家兔全血粘度和红细胞聚集指数等大部分;The experimental results are referring to Table 1, Table 2, Table 3, Table 4 and Fig. 1. Through statistical analysis, the results show that the triglycerides, total cholesterol, and low-density lipoproteins of quail and rabbits are all higher than normal by using the extract of the present invention. group but significantly lower than the model group and the differences were statistically significant, indicating that the drug has a better effect of lowering blood lipids; hemorheology indicators show that the drug can effectively reduce rabbit whole blood viscosity and erythrocyte aggregation index;
表1猕猴桃全株对动脉粥样硬化家兔SOD及脂质代谢的影响(mmol/l,x±s,n=8).Table 1 Effects of whole kiwifruit plants on SOD and lipid metabolism in rabbits with atherosclerosis (mmol/l, x±s, n=8).
表2猕猴桃果实对动脉粥样硬化家兔血液流变学的影响(x±s,正常组n=4,其它两组n=3).Table 2 Effect of kiwi fruit on hemorheology in rabbits with atherosclerosis (x±s, n=4 in normal group, n=3 in other two groups).
表3猕猴桃全株对动脉粥样硬化鹌鹑脂质代谢的影响(mmol/l,x±s,n=10).Table 3 Effects of whole kiwifruit plants on lipid metabolism in atherosclerotic quails (mmol/l, x±s, n=10).
表4猕猴桃全株对动脉粥样硬化鹌鹑血液流变学的影响(x±s,n=10).Table 4 Effect of whole kiwifruit plant on hemorheology of atherosclerotic quail (x±s, n=10).
以上所述是本发明的较佳实施例及其所运用的技术原理,对于本领域的技术人员来说,在不背离本发明的精神和范围的情况下,任何基于本发明技术方案基础上的等效变换、简单替换等显而易见的改变,均属于本发明保护范围之内。The above are the preferred embodiments of the present invention and the technical principles used therefor. For those skilled in the art, without departing from the spirit and scope of the present invention, any technical solution based on the present invention Obvious changes such as equivalent transformation and simple replacement all fall within the protection scope of the present invention.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910748101.XA CN110496144A (en) | 2019-08-14 | 2019-08-14 | Preparation method of kiwi fruit extract and its application in preventing and treating cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910748101.XA CN110496144A (en) | 2019-08-14 | 2019-08-14 | Preparation method of kiwi fruit extract and its application in preventing and treating cardiovascular and cerebrovascular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110496144A true CN110496144A (en) | 2019-11-26 |
Family
ID=68587420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910748101.XA Pending CN110496144A (en) | 2019-08-14 | 2019-08-14 | Preparation method of kiwi fruit extract and its application in preventing and treating cardiovascular and cerebrovascular diseases |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110496144A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101522204A (en) * | 2006-05-05 | 2009-09-02 | 欧博康有限公司 | Kiwi extract |
CN101584718A (en) * | 2008-05-19 | 2009-11-25 | 中国人民解放军第二军医大学 | Antisepalous kiwi fruit leaf extractive as well as preparation method and application thereof |
CN103415298A (en) * | 2010-12-07 | 2013-11-27 | 奥斯陆大学 | Cardio-protective agents from kiwifruits |
CN104825505A (en) * | 2015-04-29 | 2015-08-12 | 中国人民解放军第二军医大学 | Actinidia valvata leaf composition for preventing myocardial ischemia |
-
2019
- 2019-08-14 CN CN201910748101.XA patent/CN110496144A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101522204A (en) * | 2006-05-05 | 2009-09-02 | 欧博康有限公司 | Kiwi extract |
CN101584718A (en) * | 2008-05-19 | 2009-11-25 | 中国人民解放军第二军医大学 | Antisepalous kiwi fruit leaf extractive as well as preparation method and application thereof |
CN103415298A (en) * | 2010-12-07 | 2013-11-27 | 奥斯陆大学 | Cardio-protective agents from kiwifruits |
CN104825505A (en) * | 2015-04-29 | 2015-08-12 | 中国人民解放军第二军医大学 | Actinidia valvata leaf composition for preventing myocardial ischemia |
Non-Patent Citations (2)
Title |
---|
康大力等: "猕猴桃属植物化学成分及其生物活性研究进展 ", 《中成药》 * |
徐一新等: "猕猴桃属植物化学成分和生物活性研究进展 ", 《解放军药学学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maan et al. | The therapeutic properties and applications of Aloe vera: A review | |
Solihah et al. | Phytochemicals screening and total phenolic content of Malaysian Zea mays hair extracts | |
Toma et al. | The effect of aqueous leaf extract of fluted pumpkin on some hematological parameters and liver enzymes in 2, 4-dinitrophenylhydrazine-induced anemic rats | |
CN102907714B (en) | Black gingko nut health food and making method thereof | |
CN104381775A (en) | Solid honey powder having effects of reducing blood lipid and health care | |
CN110496144A (en) | Preparation method of kiwi fruit extract and its application in preventing and treating cardiovascular and cerebrovascular diseases | |
CN114532503B (en) | Red apple and cherry plum composition and application thereof in reducing blood fat | |
KR20150025545A (en) | Composition for lowering levels of lipid or glucose containing the juice of Hippophae rhamnoides L. | |
Saif et al. | Madhuca longifolia (Mahua): A comprehensive ethno pharmacological review | |
Suara et al. | Neutraceutical and antibacterial properties of methanol extract of Plukenetia conophora [Müll.-Arg. family Euphorbiaceae] leaves and physical properties of its cream formulations | |
CN103504206B (en) | Lipid lowering cake and making method thereof | |
CN108096299B (en) | Extraction and separation method of active parts of kiwi fruit seeds and its application | |
KR102050554B1 (en) | Composition for hangover treatment and manufacturing method for the same | |
CN113662975A (en) | Chenopodium quinoa willd extract and application thereof in preparation of medicines and foods for preventing gastric mucosal injury | |
KR101930145B1 (en) | Fasting supplement composition | |
CN106942439B (en) | Cyclocarya paliurus and guava leaf blood glucose reducing tea and preparation method and application thereof | |
CN1060030C (en) | "Haitong" oral liquid and its preparing method | |
Akinwale et al. | Effect of feeding various concentrations of Shea oil on some biochemical parameters in normal albino rat | |
CN115645449B (en) | Processing method and application of double-auxiliary wine honey pulp | |
CN109172628A (en) | A kind of Fructus Cucumidis sativi extract and its preparing the application in anti-cardiovascular drugs | |
POPESCU et al. | The influence of extraction solvent on the active principles content of Portulaca Oleracea native species | |
CN115530365B (en) | Pitaya-pineapple-dragon fruit compound enzyme and preparation method thereof | |
KR102651348B1 (en) | Food composition for maintaining erection and improving prostate health | |
CN110521889B (en) | A kind of compound fruit juice with auxiliary weight loss and lipid lowering effect and preparation method thereof | |
Eliseeva et al. | Peach (lat. Persicus) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191126 |
|
WD01 | Invention patent application deemed withdrawn after publication |